Chronic Myeloid Leukemia (CML)

 

LBH589 with Imatinib Mesylate for CML (2412)
A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR

Investigator: Vivian Oehler, MD;   Conditions: Chronic Myeloid Leukemia (CML);    Status: Recruiting;   Study ID: NCT00686218